{"id":2309,"date":"2014-12-01T12:06:00","date_gmt":"2014-12-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/verordung-von-noak-nachdenken-und-abwaegen"},"modified":"2014-12-01T12:06:00","modified_gmt":"2014-12-01T11:06:00","slug":"verordung-von-noak-nachdenken-und-abwaegen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/verordung-von-noak-nachdenken-und-abwaegen","title":{"rendered":"Verordung von NOAK: Nachdenken und abw\u00e4gen!"},"content":{"rendered":"<p>Die neuen oralen Antikoagulanzien (NOAK) sind zur Prophylaxe von Schlaganf\u00e4llen bei Patienten mit Vorhofflimmern, bei der Therapie tiefer Venenthrombosen und pulmonaler Embolien etwa gleich effektiv wie Vitamin-K-Antagonisten (VKA). Unter einer Behandlung mit NOAK kommt es um 50% seltener zu intrazerebralen Blutungen. Der absolute Unterschied in der H\u00e4ufigkeit intrazerebraler Blutungen ist jedoch klein: nach einer Metaanalyse [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die neuen oralen Antikoagulanzien (NOAK) sind zur Prophylaxe von Schlaganf\u00e4llen bei Patienten mit Vorhofflimmern, bei der Therapie tiefer Venenthrombosen und pulmonaler Embolien etwa gleich effektiv wie Vitamin-K-Antagonisten (VKA). Unter einer Behandlung mit NOAK kommt es um 50% seltener zu intrazerebralen Blutungen. Der absolute Unterschied in der H\u00e4ufigkeit intrazerebraler Blutungen ist jedoch klein: nach einer Metaanalyse [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,137,1322,60,4379,184,523,524,2305,1314,1312,2068,2067,187,68,1328,1327,138,2727,183,2304,3254,56,181,136],"class_list":["post-2309","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-antikoagulanzien","tag-apixaban","tag-apoplektischer-insult","tag-aristotle-studie","tag-arrhythmien","tag-arzneimittelverordnungen","tag-arzneiverordnungen","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-engage-af-timi-48-studie","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-re-ly-studie","tag-rhythmusstoerungen","tag-rivaroxaban","tag-rocket-af-studie","tag-schlaganfall","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2309"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2309\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}